SciBase has signed a Collaboration and License Agreement with Castle Biosciences to develop diagnostic tests within dermatology and intends to carry out a directed share issue of approximately MSEK 30

STOCKHOLM, Sweden – June 16, 2025 – SciBase Holding AB (“SciBase”) [STO: SCIB], a leading developer of AI-based diagnostic solutions for skin disorders, today announced it has signed a collaboration and license agreement with Castle Biosciences (Nasdaq: CSTL), a US-based leader in molecular diagnostics. The initial goal of the collaboration is to develop a test that predicts flares in patients diagnosed with atopic dermatitis (AD). The method will be based on SciBase’s EIS technology and specifically, Nevisense, inclusive of both the desktop and point-of care devices. In connection with the